Intervention not reported
Maternal satisfaction with analgesia (assessed 3 days postpartum)
1 finding from 1 review
- no estimate extractedStudies not reportedLow
Findings
What do systematic reviews say?
3,454 questions · 3,562 findings · 816 reviews · Headline outcomes only
No studies found 538 · 15.1%GRADE not reported 239 · 6.7%Very low 933 · 26.2%Low 1,041 · 29.2%Moderate 612 · 17.2%High 199 · 5.6%
Intervention not reported
Maternal pan score or pain measured in labour (rated as good one day after birth)
1 finding from 1 review
- no estimate extractedStudies not reportedVery low
Intervention not reported
Maternal pain score or pain measured in labour (measured 1 day after delivery)
1 finding from 1 review
- no estimate extractedStudies not reportedVery low
Hypocaloric nutrition vs control
Mortality at 30 days: 28 to 30 days all‐cause mortality · critically ill adult patients
1 finding from 1 review
- Prescribed hypocaloric nutrition support for critically‐ill adults 2018 · Cochrane Headline outcomes onlyno estimate extracted7 studies · 2611 participantsVery low
Hypocaloric nutrition vs control
Length of hospital stay · critically ill adult patients
1 finding from 1 review
- Prescribed hypocaloric nutrition support for critically‐ill adults 2018 · Cochrane Headline outcomes onlyno estimate extracted10 studies · 1677 participantsVery low
Hypocaloric nutrition vs control
ICU length of stay (general intensive care patients) · critically ill adult patients
1 finding from 1 review
- Prescribed hypocaloric nutrition support for critically‐ill adults 2018 · Cochrane Headline outcomes onlyno estimate extracted11 studies · 2942 participantsVery low
Hypocaloric nutrition vs control
Duration of mechanical ventilation · critically ill adult patients
1 finding from 1 review
- Prescribed hypocaloric nutrition support for critically‐ill adults 2018 · Cochrane Headline outcomes onlyno estimate extracted12 studies · 3000 participantsVery low
Cervical dilatation vs no dilatation
Febrile morbidity · women with non‐labour caesarean section
Cervical dilatation showed no clear difference in febrile morbidity (at least 38° Celsius, measured on 2/10 days… compared with no dilatation (low certainty).
1 finding from 1 review
- Mechanical dilatation of the cervix during elective caesarean section before the onset of labour for reducing… 2018 · Cochrane Headline outcomes onlyRR 1.18 [0.76, 1.85]7 studies · 2126 participantsLow
Single dose primaquine at 0.75 mg/kg vs no primaquine, with artemisinin partner,
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.75 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
- Primaquine or other 8‐aminoquinolines for reducing Plasmodium falciparum transmission 2018 · Cochrane Headline outcomes onlyRR 0.31 [0.23, 0.43]5 studies · 793 participantsHigh
Single dose primaquine at 0.4 to 0.5 mg/kg vs no primaquine, with non‐artemisinin partner,
Participants with gametocytes at day 4‐5, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.4 to 0.5 mg/kg showed no clear difference in participants with gametocytes at day 4‐5, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
- Primaquine or other 8‐aminoquinolines for reducing Plasmodium falciparum transmission 2018 · Cochrane Headline outcomes onlyRR 0.83 [0.62, 1.13]2 studies · 221 participantsModerate
Single dose primaquine at 0.4 to 0.5 mg/kg vs no primaquine, with non‐artemisinin partner,
Participants with gametocytes at day 8, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.4 to 0.5 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
- Primaquine or other 8‐aminoquinolines for reducing Plasmodium falciparum transmission 2018 · Cochrane Headline outcomes onlyRR 0.6 [0.49, 0.75]2 studies · 216 participantsModerate
Single dose primaquine at 0.75 mg/kg vs no primaquine, with non‐artemisinin partner,
Participants infectious at day 8 · adults and children with malaria being treated with non‐artemisinin treatment
It is very uncertain whether single dose primaquine at 0.75 mg/kg changes participants infectious at day 5 compared with no primaquine, with non‐artemisinin partner, (very low certainty).
2 findings from 1 review
- Primaquine or other 8‐aminoquinolines for reducing Plasmodium falciparum transmission 2018 · Cochrane Headline outcomes onlyRR 0.09 [0.01, 0.62]2 studies · 30 participantsVery low
- Primaquine or other 8‐aminoquinolines for reducing Plasmodium falciparum transmission 2018 · Cochrane Headline outcomes onlyRR 0.07 [0.01, 0.45]2 studies · 30 participantsVery low
Single dose primaquine at 0.75 mg/kg vs no primaquine, with non‐artemisinin partner,
Participants with gametocytes at day 5, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.75 mg/kg showed no clear difference in participants with gametocytes at day 5, by microscopy compared with no primaquine, with non‐artemisinin partner, (low certainty).
1 finding from 1 review
- Primaquine or other 8‐aminoquinolines for reducing Plasmodium falciparum transmission 2018 · Cochrane Headline outcomes onlyRR 0.85 [0.48, 1.5]2 studies · 52 participantsLow
Single dose primaquine at 0.75 mg/kg vs no primaquine, with non‐artemisinin partner,
Participants with gametocytes at day 8, by microscopy · adults and children with malaria being treated with non‐artemisinin treatment
Single dose primaquine at 0.75 mg/kg probably leads to lower participants with gametocytes at day 8, by microscopy compared with no primaquine, with non‐artemisinin partner, (moderate certainty).
1 finding from 1 review
- Primaquine or other 8‐aminoquinolines for reducing Plasmodium falciparum transmission 2018 · Cochrane Headline outcomes onlyRR 0.39 [0.25, 0.62]4 studies · 186 participantsModerate
Single dose primaquine at 0.2 to 0.25 mg/kg vs no primaquine, with artemisinin partner,
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.2 to 0.25 mg/kg leads to lower participants with gametocytes at day 8 by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
- Primaquine or other 8‐aminoquinolines for reducing Plasmodium falciparum transmission 2018 · Cochrane Headline outcomes onlyRR 0.52 [0.41, 0.65]4 studies · 532 participantsHigh
Single dose primaquine at 0.4 to 0.5 mg/kg vs no primaquine, with artemisinin partner,
Participants with gametocytes at day 8, by PCR · adults and children with malaria being treated with artemisinin combination treatment
Single dose primaquine at 0.4 to 0.5 mg/kg leads to lower participants with gametocytes at day 8, by PCR compared with no primaquine, with artemisinin partner, (high certainty).
1 finding from 1 review
- Primaquine or other 8‐aminoquinolines for reducing Plasmodium falciparum transmission 2018 · Cochrane Headline outcomes onlyRR 0.37 [0.29, 0.48]5 studies · 758 participantsHigh
Higher dose vitamin K vs lower dose vitamin K
Presence of PIVKA II at day 5: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
- Prophylactic vitamin K for the prevention of vitamin K deficiency bleeding in preterm neonates 2018 · Cochrane Headline outcomes onlyRR 1.36 [0.24, 7.57]1 study · 61 participantsLow
Higher dose vitamin K vs lower dose vitamin K
Presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM · preterm infants
Higher dose vitamin K showed no clear difference in presence of PIVKA II at day 25: 0.2 mg IM versus 0.5 mg IM compared with lower dose vitamin K (low certainty).
1 finding from 1 review
- Prophylactic vitamin K for the prevention of vitamin K deficiency bleeding in preterm neonates 2018 · Cochrane Headline outcomes onlyRR 0.96 [0.06, 14.6]1 study · 53 participantsLow
Intramuscular vitamin K vs intravenous vitamin K
Presence of PIVKA II at day 5: 0.2 mg IV versus 0.2 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IV versus 0.2 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
- Prophylactic vitamin K for the prevention of vitamin K deficiency bleeding in preterm neonates 2018 · Cochrane Headline outcomes onlyRR 1.52 [0.37, 6.23]1 study · 60 participantsLow
Intramuscular vitamin K vs intravenous vitamin K
Presence of PIVKA II at day 5: 0.2 mg IV versus 0.5 mg IM · preterm infants
Intramuscular vitamin K showed no clear difference in presence of PIVKA II at day 5: 0.2 mg IV versus 0.5 mg IM compared with intravenous vitamin K (low certainty).
1 finding from 1 review
- Prophylactic vitamin K for the prevention of vitamin K deficiency bleeding in preterm neonates 2018 · Cochrane Headline outcomes onlyRR 2.07 [0.41, 10.43]1 study · 57 participantsLow